Education > XRAY > Search Results

FORCE's eXaming the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

1 through 10 of 10

Relevance: Medium

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline

Update : FDA updates reported harmful events linked to breast implants

Most relevant for: People who have or are considering breast implants.

The FDA has updated reported cases of breast implant-associated cancer and breast implant illness. Included in this update is approval of a questionnaire that asks about quality of life and satisfaction with breast implants. (10/20/20)

Read More
FDA updates reported harmful events linked to breast implants

Relevance: High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline

Guideline : FDA asks Allergan to recall certain textured breast implants

Most relevant for: Women with, or considering breast reconstruction with implants

On July 25, 2019, the Food and Drug Administration requested that breast implant manufacturer Allergan recall its BIOCELL textured implants and expanders due to an association with a rare type of lymphoma called Breast Implant Associated Anaplastic Large Cell Lymphoma or BIA-ALCL. The FDA does not recommend removing implants for people who do not have disease symptoms. This XRAYS review updates information about this FDA recall. (7/29/19)

Read More
FDA asks Allergan to recall certain textured breast implants

Relevance: Medium-Low

pointerRelevance

Strength of Science: Low

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline

Study : Breast cancer implant study suggests links with illness but has serious flaws

Most relevant for: Women with or considering breast implant reconstruction

Summary

An article in the Annals of Surgery, researchers conclude that their work supports an association between silicone breast implants and a range of conditions. This journal article was accompanied by two editorials in which experts voiced their disagreement with the way the analysis was performed and the conclusions of the authors. (2/21/19)

Read More
Breast cancer implant study suggests links with illness but has serious flaws

Relevance: High

pointerRelevance

Quality of Writing: Medium-High

pointerQuality of Writing

Personal Story : Juliet's story: No reconstruction is a post-mastectomy option

Most relevant for: Women who have had or are considering mastectomy without reconstruction

In a March 2018 article from breastcancercare.org, Juliet conveys her personal experience with a breast cancer diagnosis and her decision to not have her breasts reconstructed after her mastectomy. She details the emotional complexity of her thought process and the empowerment she felt in her decisions. (5/24/18)

Read More
Juliet's story: No reconstruction is a post-mastectomy option

Relevance: Medium-High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline

Study : FDA updates report on risk of lymphoma from breast implants

Most relevant for: Women who currently have textured implants or expanders or who have had them in the past

Note: On 07/25/19, the FDA announced a recall of Allergan BIOCELL textured implants and expanders, due to their association with BIA-ALCL. 

In March 2017, the Food and Drug Administration reported that patients with breast implants may be at increased risk for a rare type of lymphoma. This was covered in a previous XRAYS review. The FDA has continued to collect data since the first reported association in 2011. Recently, the agency released an update on the number of reported cases of breast implant-associated lymphoma and lifetime risk estimates for women with textured breast implants. (04/02/18)

Read More
FDA updates report on risk of lymphoma from breast implants

Relevance: Medium

pointerRelevance

Quality of Writing: Medium-High

pointerQuality of Writing

Article : Oncoplastic breast-conserving surgery with BioZorb® technology

Most relevant for: Women undergoing lumpectomy for breast cancer

The January 22, 2018 issue of The Columbian included an interview with Dr. Anne Peled in its online report, “Breast cancer surgeon diagnosed with breast cancer advocates oncoplastic surgery.”  Dr. Peled is a 37-year-old breast cancer surgeon and plastic surgeon from California who was recently diagnosed with breast cancer. She underwent oncoplastic lumpectomy—a single surgery that removes the tumor and rearranges the remaining tissue to eliminate any resulting breast deformity. Peled’s procedure included a relatively new technology that she uses for her own patients: an implanted BioZorb® marker, a small device that improves precise targeting of radiation therapy and cosmetic outcome. (2/8/18) 

Read More
Oncoplastic breast-conserving surgery with BioZorb® technology

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline

Study : What is the risk of breast cancer recurrence after nipple-sparing mastectomy?

Most relevant for: Breast cancer patients who are considering or have had a nipple sparing mastectomy

Nipple-sparing mastectomy (NSM) offers better cosmetic results for women who have immediate breast reconstruction (at the same time as their mastectomy). Over the past decade, NSM has gained popularity among surgeons and patients. Studies show that women who keep their own nipples have higher rates of satisfaction and psychological well-being after mastectomy and reconstruction compared to women who lose their nipples. However, little data exists on the long-term risk of recurrence following NSM. New research adds to a growing body of evidence suggesting that risk of recurrence is low after NSM in carefully selected patients with breast cancer. (1/25/18)

Read More
What is the risk of breast cancer recurrence after nipple-sparing mastectomy?

Relevance: Medium-High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline

Study : FDA report claims women with breast implants may be at risk for rare cancer

Most relevant for: Women who had or are consideration breast reconstruction with implants

THIS INFORMATION HAS BEEN UPDATED. The FDA issued an update in March, 2018 about Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). This was covered in a more recent XRAY review. On 07/25/19, the FDA announced a recall of Allergan BIOCELL textured implants and expanders, due to their association with BIA-ALCL. This was also covered in a more recent XRAY review.

Recent headlines highlighted an FDA report stating that patients with breast implants may be at increased risk for a rare type of non-Hodgkin lymphoma. What is the scientific evidence behind this claim? (4/21/17)

Read More
FDA report claims women with breast implants may be at risk for rare cancer

Relevance: Medium-High

pointerRelevance

Quality of Writing: Medium-High

pointerQuality of Writing

Article : After mastectomy: reconstruct or not?

Most relevant for: Woman who are facing mastectomy

Today, more women know they can have breast reconstruction after removing their breasts for cancer treatment or risk reduction. But what about choosing not to undergo reconstruction? Roni Caryn Rabin writes about the experiences of women who decide against reconstruction in her New York Times piece “‘Going Flat’ After Breast Cancer.” (12/14/16)

Read More
After mastectomy: reconstruct or not?

Relevance: Medium

pointerRelevance

Strength of Science: Medium

pointerStrength of Science

Study : More patients with invasive breast cancer opting for double mastectomies

Most relevant for: Women diagnosed with breast cancer who are recommended to undergo a single mastectomy

Women diagnosed with invasive breast cancer have a number of surgical options. They can have breast-conserving surgery (lumpectomy) with radiation, a unilateral (single) mastectomy to remove only the tissue from the cancerous breast, or a contralateral prophylactic mastectomy (CPM), which removes both breasts. A new study finds that more women are opting for CPM, yet overall survival for these patients is not increasing. (5/3/2016)

Read More
More patients with invasive breast cancer opting for double mastectomies